Takeda’s narcolepsy data reveal why orexin agonists are becoming a neuroscience priority
Find out how Takeda’s oveporexton data could reshape narcolepsy type 1 care as approval, safety and access questions loom.
Pharma & Biotech
Pharma & Biotech
Why the FDA hearing on Vanda Pharmaceuticals’ HETLIOZ could reshape drug approval challenges
FDA grants rare hearing to review Vanda Pharmaceuticals’ HETLIOZ jet lag application. Discover what this regulatory fight could mean for circadian medicine.